PTSM: Pharmaceutical Technology Sourcing and Management, Jul 11, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Jul 11, 2012
Biologics
Biosimilars: Market Weaknesses and Strengths
By Patricia Van Arnum
Biosimilars represent an emerging niche in the biopharmaceutical market, but how strong is their true potential?
Outsourcing
Biomanufacturing Innovation
By Eric Langer
Industry wants more innovation, but can suppliers meet customer needs?
Global Feature
What is Ahead in Chemical API Manufacturing
By Patricia Van Arnum
Flow chemistry and microreactors offer an alternative to traditional batch manufacturing.
New Models in Contract Services
By Patricia Van Arnum
Sponsor companies' increasing focus on strategic outsourcing has changed the rules of the game.
Decades of Change for the Top Pharmaceutical Companies
By Patricia Van Arnum
Tracking change from spinoffs of chemical companies to life-sciences powerhouses.
A Look into the Future: The Pharmaceutical Company of 2020
By Patricia Van Arnum
How will the pharmaceutical company of 2020 be different from the pharmaceutical company of 2010? A look at emerging business models and the factors influencing the direction of the global pharmaceutical industry.
CSR and Sustainability Forum
The UN at the Sustainability Table
By Patricia Van Arnum
Highlights of UN Conference on Sustainable Development, held in Rio de Janeiro, Brazil, last month and related industry initiatives.
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here